Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Update of Adjuvant Chemotherapy for Resected Gastric Cancer

  • Oh, Sang-Cheul (Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Korea University)
  • Received : 2012.02.29
  • Accepted : 2012.03.05
  • Published : 2012.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.

Keywords

References

  1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  2. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077. https://doi.org/10.1200/JCO.2004.08.026
  3. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. JAMA 2010;303:1729-1737. https://doi.org/10.1001/jama.2010.534
  4. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  5. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315. https://doi.org/10.1016/S1470-2045(06)70623-4
  6. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732. https://doi.org/10.1038/sj.bjc.6601761
  7. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064. https://doi.org/10.1016/S0959-8049(99)00076-3
  8. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608. https://doi.org/10.1080/11024150201680005
  9. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 2006;18:311-317. https://doi.org/10.1179/joc.2006.18.3.311
  10. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-843. https://doi.org/10.1023/A:1008377101672
  11. Zhao SL, Fang JY. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a metaanalysis. Cancer Invest 2008;26:317-325. https://doi.org/10.1080/07357900701834686
  12. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008;34:1208-1216. https://doi.org/10.1016/j.ejso.2008.02.002
  13. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447.
  14. Pignon JP, Ducreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994;12:877-878. https://doi.org/10.1200/JCO.1994.12.4.877
  15. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999;354:273-277. https://doi.org/10.1016/S0140-6736(99)01048-X
  16. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003;21:2282-2287. https://doi.org/10.1200/JCO.2003.06.103
  17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  18. Rougier P, Sakamoto J. Surrogate endpoints for overall survival in resectable gastric cancer and in advanced gastric carcinoma: analysis of individual data from the GASTRIC collaboration. Ann Oncol 2011;22(suppl 5):v10-18. https://doi.org/10.1093/annonc/mdr285
  19. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-1471. https://doi.org/10.1200/JCO.2010.33.6297

Cited by

  1. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer vol.43, pp.5, 2012, https://doi.org/10.3892/ijo.2013.2099
  2. Loss of COP1 expression determines poor prognosis in patients with gastric cancer vol.30, pp.4, 2012, https://doi.org/10.3892/or.2013.2664
  3. Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis vol.14, pp.1, 2012, https://doi.org/10.7314/apjcp.2013.14.1.381
  4. Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo vol.10, pp.6, 2012, https://doi.org/10.3892/mmr.2014.2598
  5. Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors vol.32, pp.4, 2012, https://doi.org/10.3892/or.2014.3344
  6. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers vol.34, pp.12, 2012, https://doi.org/10.1007/s11095-017-2202-7
  7. Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma vol.8, pp.54, 2017, https://doi.org/10.18632/oncotarget.21576
  8. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity vol.14, pp.None, 2012, https://doi.org/10.2147/dddt.s233023
  9. The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids vol.13, pp.None, 2012, https://doi.org/10.2147/ott.s237431